Investigational drug · Phase 3
BI 764198
Also called: Apecotrep
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Focal Segmental Glomerulosclerosis, Proteinuric Kidney Diseases, Kidney Disease, Chronic.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
13
Any phase or sponsor naming "BI 764198"
First trial start
2022
May 3, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI 764198", any sponsor or status.
Conditions studied
As listed on its trial records.
- Focal Segmental Glomerulosclerosis
- Proteinuric Kidney Diseases
- Kidney Disease, Chronic
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "BI 764198" as an intervention, largest first.
- A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)Pivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07220083 · 286 participants (planned) · Start Feb 16, 2026 · Primary completion Dec 27, 2028
Drug: BI 764198; Placebo · For: Focal Segmental Glomerulosclerosis
Sites: Alabaster, Alabama; Huntsville, Alabama; Surprise, Arizona · 309 sites in all
- ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19Pivotal-lookingTerminated
Boehringer IngelheimBoehringer Ingelheim
NCT04604184 · 133 participants · Start Nov 3, 2020 · Primary completion Mar 24, 2021
Drug: BI 764198; Placebo · For: COVID-19
Sites: Orange, California; Alexandria, Louisiana; Boston, Massachusetts · 25 sites in all
- PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney DiseasePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07355296 · 132 participants (planned) · Start Mar 23, 2026 · Primary completion Jan 20, 2028
Drug: BI 764198; Placebo matching BI 764198 · For: Proteinuric Kidney Diseases
Sites: Huntsville, Alabama; Glendale, California; Granada Hills, California · 153 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03854552 · 72 participants · Start Mar 15, 2019 · Primary completion Aug 7, 2019
Drug: BI 764198; Placebo · For: Healthy
Sites: Mannheim, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT05213624 · 67 participants · Start May 3, 2022 · Primary completion Jan 3, 2025
Drug: BI 764198; Placebo · For: Kidney Disease, Chronic
Sites: Huntsville, Alabama; San Francisco, California; South Gate, California · 54 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT04102462 · 52 participants · Start Oct 29, 2019 · Primary completion Oct 8, 2020
Drug: BI 764198; Matching placebo · For: Healthy
Sites: Mannheim, Germany
- A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are ToleratedCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT04665700 · 44 participants · Start Feb 6, 2021 · Primary completion Oct 16, 2021
Drug: BI 764198; Placebo · For: Healthy
Sites: Tokyo, Sumida-ku, Japan
Boehringer IngelheimBoehringer Ingelheim
NCT04176536 · 28 participants · Start Dec 10, 2019 · Primary completion Nov 17, 2020
Drug: BI 764198 · For: Healthy; Chronic Kidney Disease
Sites: Kiel, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT04656288 · 28 participants · Start Jan 15, 2021 · Primary completion Mar 15, 2021
Drug: BI 764198 - Formula A; BI 764198 - Formula B and 2 more · For: Healthy
Sites: Antwerp, Belgium
Boehringer IngelheimBoehringer Ingelheim
NCT05863130 · 24 participants · Start May 3, 2023 · Primary completion Nov 9, 2023
Drug: BI 764198 (C-14) (approach 1); BI 764198 (C-14) (approach 2) · For: Healthy
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Angiotensin system modulation in focal segmental glomerulosclerosis: pharmacological basis and clinical implications.
Gembillo G, Casuscelli C, La Spada A, et al. · Expert Opin Pharmacother 2026
- TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198.
Trachtman H, Kretzler M, Gesualdo L, et al. · Lancet 2026
- Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment.
Schultz A, Halabi A, Seitz F, et al. · Expert Opin Investig Drugs 2025
- A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men.
Yonemura T, Sarashina A, Tachibana Y, et al. · Expert Opin Investig Drugs 2025
- Natural History and Clinicopathological Associations of TRPC6-Associated Podocytopathy.
Wooden B, Beenken A, Martinelli E, et al. · J Am Soc Nephrol 2025
- TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design.
Trachtman H, Kretzler M, Desmond HE, et al. · Kidney Int Rep 2023
Also in development for Focal Segmental Glomerulosclerosis
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- R3R01Phase 22 trials
River 3 Renal Corp. · Diabetic Kidney Disease, Alport Syndrome, Focal Segmental Glomerulosclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.